Our Environmental, Social and Governance (ESG) strategy and efforts directly support Lilly’s purpose to discover and develop medicines that make life better. We are striving to:
expand equitable access to medicines for more people around the world
improve health care for people living in areas with limited resources
strengthen communities and address social issues – like racial justice and education – that matter to our business, employees and society
empower a diverse workforce, harnessing a variety of perspectives to discover and deliver medicines
minimize our environmental impact across the life cycles of our products and our supply chains
operate ethically and responsibly, guided by our core values of integrity, excellence and respect for people.
Our ESG goals are integrated into our business strategy and operations. We set ambitious, measurable goals and report on our progress through this site and other communications with stakeholders.
Our Board is actively engaged in the identification and oversight of strategic ESG matters at Lilly. Our CEO and Executive Committee are responsible for management of our ESG goals and have ESG commitments embedded into their personal performance targets. In addition, we actively engage our global employees in our ESG efforts where they may have individual and collective impact.
Lilly's ESG Priorities
Stakeholder Engagement and Topic Identification
Lilly solicits input from internal and external people and organizations to better determine the ESG issues that matter most to our company and stakeholders. We obtain input and prioritization from:
In addition to engaging with stakeholders, we frequently conduct peer benchmarking and integrate industry and sustainability trends, as well as leverage relevant sustainability reporting frameworks, including the Sustainability Accounting Standards Board (SASB), Task Force on Climate-related Financial Disclosures (TCFD), among others.
Through this process, we focus on the 14 ESG topics noted above, which represent issues that we believe are most important to internal and external stakeholders and are key to our company’s long-term success. These topics are aligned with the SASB standards for the Biotechnology and Pharmaceutical industry, as well as environmental issues addressed by TCFD. Our ESG strategy is dynamic, and we review these priorities periodically to align our approach with topics that are relevant for Lilly, our stakeholders and our industry.
See important information about our ESG report.